These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 22736575)

  • 1. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
    Passie T; Emrich HM; Karst M; Brandt SD; Halpern JH
    Drug Test Anal; 2012; 4(7-8):649-59. PubMed ID: 22736575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention.
    Mizrachi Zer-Aviv T; Segev A; Akirav I
    Behav Pharmacol; 2016 Oct; 27(7):561-9. PubMed ID: 27551883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the endocannabinoid system to treat anxiety-related disorders.
    Korem N; Zer-Aviv TM; Ganon-Elazar E; Abush H; Akirav I
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):193-202. PubMed ID: 26426887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
    Orsolini L; Chiappini S; Volpe U; Berardis D; Latini R; Papanti GD; Corkery AJM
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cannabinoids for the treatment of patients with post-traumatic stress disorder.
    Forsythe ML; Boileau AJ
    J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):121-132. PubMed ID: 33662194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.
    Chadwick VL; Rohleder C; Koethe D; Leweke FM
    Curr Opin Psychiatry; 2020 Jan; 33(1):20-42. PubMed ID: 31714262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.
    Papini S; Sullivan GM; Hien DA; Shvil E; Neria Y
    Biol Psychol; 2015 Jan; 104():8-18. PubMed ID: 25448242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.
    Hill MN; Campolongo P; Yehuda R; Patel S
    Neuropsychopharmacology; 2018 Jan; 43(1):80-102. PubMed ID: 28745306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder.
    Betthauser K; Pilz J; Vollmer LE
    Am J Health Syst Pharm; 2015 Aug; 72(15):1279-84. PubMed ID: 26195653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder.
    Ney LJ; Matthews A; Bruno R; Felmingham KL
    Neurosci Biobehav Rev; 2018 Nov; 94():302-320. PubMed ID: 30017748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids as therapeutics for PTSD.
    Sbarski B; Akirav I
    Pharmacol Ther; 2020 Jul; 211():107551. PubMed ID: 32311373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings.
    Berardi A; Schelling G; Campolongo P
    Pharmacol Res; 2016 Sep; 111():668-678. PubMed ID: 27456243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review.
    Steenkamp MM; Blessing EM; Galatzer-Levy IR; Hollahan LC; Anderson WT
    Depress Anxiety; 2017 Mar; 34(3):207-216. PubMed ID: 28245077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology for sleep disturbance in PTSD.
    Lipinska G; Baldwin DS; Thomas KG
    Hum Psychopharmacol; 2016 Mar; 31(2):156-63. PubMed ID: 26856810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glucocorticoids, catecholamines and endocannabinoids in the development of traumatic memories and posttraumatic stress symptoms in survivors of critical illness.
    Hauer D; Kaufmann I; Strewe C; Briegel I; Campolongo P; Schelling G
    Neurobiol Learn Mem; 2014 Jul; 112():68-74. PubMed ID: 24125890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis for posttraumatic stress disorder: A neurobiological approach to treatment.
    Krumm BA
    Nurse Pract; 2016 Jan; 41(1):50-4. PubMed ID: 26678423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder.
    Neumeister A; Seidel J; Ragen BJ; Pietrzak RH
    Psychoneuroendocrinology; 2015 Jan; 51():577-84. PubMed ID: 25456347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.
    Fattore L; Piva A; Zanda MT; Fumagalli G; Chiamulera C
    Psychopharmacology (Berl); 2018 Feb; 235(2):433-445. PubMed ID: 29178010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.